Skip to content
Home
About Us
Our Goal
Management Team
Board of Directors
Scientific Advisory Board
Technology Platform
The Challenge
Platform
Our Focus
Focus Areas
Pipeline
Osteoporosis
Hypoparathyroidism
Investors
Share Information
Share Chart
Email Alerts
Press Releases
SEC Filing
Investor Calendar
Corporate Governance
Board of Directors
Management
Committee Composition
Investor Resources
Investor FAQs
Document Request
Email Alerts
Corporate Presentation
News & Events
Contact Us
Menu
Home
About Us
Our Goal
Management Team
Board of Directors
Scientific Advisory Board
Technology Platform
The Challenge
Platform
Our Focus
Focus Areas
Pipeline
Osteoporosis
Hypoparathyroidism
Investors
Share Information
Share Chart
Email Alerts
Press Releases
SEC Filing
Investor Calendar
Corporate Governance
Board of Directors
Management
Committee Composition
Investor Resources
Investor FAQs
Document Request
Email Alerts
Corporate Presentation
News & Events
Contact Us
Publications
Osteoporosis
ASBMR 2022 Poster
ASBMR 2021 Presentation - 6 Month BMD
ASBMR 2021 Poster - Bone Markers
ASBMR 2018 Poster
ASBMR 2023 Poster 1
2017 ASBMR Poster
2016 ASBMR Poster
2014 ASBMR Poster (Entera +UEA)
2013 ASBMR Poster
ASBMR 2023 Poster 2
Hypoparathyroidism
Entera Hypo Paper in JBMR June 2021
2019 ASBMR Poster
2015 ASBMR Poster PH2a HypoPT
Platform
Technology
The Combined Effect of Permeation Enhancement and Proteolysis Inhibition on the Systemic Exposure of Orally Administrated Peptides
Other Targets
Oral Delivery Technology Enabling Gastro-Mucosal Absorption of Glucagon-Like-Peptide-2 Analog (Teduglutide) - A Novel Approach for Injection-Free Treatment of Short Bowel Syndrome
Thank You
Message Sent!
We will get back to you soon
